CTLA4 and hepatocellular carcinoma: A phase I/II trial recruited HCC patients unsuccessfully treated with sorafenib and administered cabozantinib (TKI) 40 mg per day with nivolumab (ICI, anti-PD-1 antibody) 240 mg on the first day of 14-day cycles (doublet immunotherapy), or cabozantinib 40 mg per day with nivolumab 3 mg/kg once every 14 days, along with ipilimumab (ICI, anti-CTLA-4 antibody) 1 mg/kg once after 1.5 months (triplet immunotherapy) [60].